Shares of Humacyte Inc. (HUMA) closed yesterday's trading at $7.71, which marks a year-to-date gain of over 160%.
This clinical-stage biotechnology platform company is involved in the manufacture of human acellular vessels, or HAVs, in varying sizes to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement.
Humacyte's Human Acellular Vessel (HAV), proposed for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible, is under priority review by the FDA, with a decision expected on Aug.10, 2024.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.